Loading...

Cyclacel Pharmaceuticals

DB:UXI3
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UXI3
DB
$12M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Cyclacel Pharmaceuticals has significant price volatility in the past 3 months.
UXI3 Share Price and Events
7 Day Returns
-3.1%
DB:UXI3
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-46.4%
DB:UXI3
-10.6%
DE Biotechs
-6.2%
DE Market
UXI3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cyclacel Pharmaceuticals (UXI3) -3.1% -27.9% -3.7% -46.4% -84.9% -97.8%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • UXI3 underperformed the Biotechs industry which returned -10.6% over the past year.
  • UXI3 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
UXI3
Industry
5yr Volatility vs Market

Value

 Is Cyclacel Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cyclacel Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.622.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cyclacel Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cyclacel Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:UXI3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.62
NasdaqCM:CYCC Share Price ** NasdaqCM (2019-04-23) in USD $0.7
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cyclacel Pharmaceuticals.

DB:UXI3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CYCC Share Price ÷ EPS (both in USD)

= 0.7 ÷ -0.62

-1.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cyclacel Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cyclacel Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cyclacel Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:UXI3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.14x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cyclacel Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cyclacel Pharmaceuticals's assets?
Raw Data
DB:UXI3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.22
NasdaqCM:CYCC Share Price * NasdaqCM (2019-04-23) in USD $0.7
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:UXI3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CYCC Share Price ÷ Book Value per Share (both in USD)

= 0.7 ÷ 1.22

0.58x

* Primary Listing of Cyclacel Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cyclacel Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cyclacel Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cyclacel Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cyclacel Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-171.3%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Cyclacel Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Cyclacel Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cyclacel Pharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
  • Cyclacel Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:UXI3 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:UXI3 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -171.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:UXI3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:UXI3 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0 1
2019-12-31 0 -11 2
DB:UXI3 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -7 -7
2018-09-30 -7 -8
2018-06-30 -7 -14
2018-03-31 -6 -15
2017-12-31 -7 -15
2017-09-30 0 -8 -16
2017-06-30 0 -10 -10
2017-03-31 1 -11 -11
2016-12-31 1 -10 -12
2016-09-30 1 -10 -13
2016-06-30 1 -11 -12
2016-03-31 2 -13 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cyclacel Pharmaceuticals is high growth as no earnings estimate data is available.
  • Cyclacel Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:UXI3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Cyclacel Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UXI3 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 -0.86 -0.86 -0.86 1.00
DB:UXI3 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.62
2018-09-30 -0.63
2018-06-30 -1.25
2018-03-31 -1.53
2017-12-31 -1.95
2017-09-30 -2.74
2017-06-30 -2.37
2017-03-31 -2.80
2016-12-31 -3.50
2016-09-30 -4.06
2016-06-30 -4.17
2016-03-31 -4.35

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cyclacel Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cyclacel Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cyclacel Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cyclacel Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cyclacel Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cyclacel Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cyclacel Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cyclacel Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cyclacel Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cyclacel Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UXI3 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.15 -7.49 5.37
2018-09-30 -7.51 5.35
2018-06-30 -14.31 5.25
2018-03-31 -14.64 5.24
2017-12-31 -14.85 5.25
2017-09-30 0.28 -15.65 5.32
2017-06-30 0.48 -9.73 5.44
2017-03-31 0.70 -10.51 5.51
2016-12-31 0.84 -11.99 5.52
2016-09-30 0.99 -12.53 5.73
2016-06-30 1.50 -12.29 5.66
2016-03-31 1.57 -12.67 5.65
2015-12-31 1.94 -14.54 5.73
2015-09-30 1.77 -15.97 5.62
2015-06-30 1.79 -18.17 5.85
2015-03-31 1.85 -19.64 5.90
2014-12-31 1.73 -19.61 5.89
2014-09-30 1.79 -18.38 6.06
2014-06-30 1.36 -19.16 6.16
2014-03-31 1.27 -12.88 6.56
2013-12-31 1.08 -19.54 7.78
2013-09-30 0.79 -20.52 8.66
2013-06-30 0.52 -18.12 9.16
2013-03-31 0.28 -23.09 9.50
2012-12-31 0.07 -14.48 8.58
2012-09-30 0.06 -13.58 7.32
2012-06-30 -0.33 -13.36 6.59

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cyclacel Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cyclacel Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cyclacel Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cyclacel Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cyclacel Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cyclacel Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cyclacel Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cyclacel Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cyclacel Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cyclacel Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cyclacel Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cyclacel Pharmaceuticals Company Filings, last reported 3 months ago.

DB:UXI3 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 15.27 0.00 17.57
2018-09-30 16.60 0.00 18.97
2018-06-30 18.62 0.00 19.82
2018-03-31 20.40 0.00 21.73
2017-12-31 21.77 0.00 24.04
2017-09-30 23.46 0.00 26.03
2017-06-30 11.64 0.00 13.72
2017-03-31 12.82 0.00 12.86
2016-12-31 14.27 0.00 16.65
2016-09-30 16.94 0.00 18.16
2016-06-30 13.16 0.00 16.06
2016-03-31 15.90 0.00 17.25
2015-12-31 18.84 0.00 20.57
2015-09-30 21.60 0.00 22.86
2015-06-30 24.10 0.00 27.03
2015-03-31 27.03 0.00 29.50
2014-12-31 21.69 0.00 24.32
2014-09-30 24.64 0.00 26.84
2014-06-30 29.59 0.00 33.58
2014-03-31 24.98 0.00 28.30
2013-12-31 28.02 0.00 31.28
2013-09-30 29.01 0.00 34.64
2013-06-30 30.93 0.00 33.82
2013-03-31 10.23 0.00 14.29
2012-12-31 10.02 0.00 16.57
2012-09-30 13.23 0.00 17.84
2012-06-30 15.06 0.00 20.12
  • Cyclacel Pharmaceuticals has no debt.
  • Cyclacel Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cyclacel Pharmaceuticals has sufficient cash runway for 2.6 years based on current free cash flow.
  • Cyclacel Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -25.7% each year.
X
Financial health checks
We assess Cyclacel Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cyclacel Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cyclacel Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cyclacel Pharmaceuticals dividends.
If you bought €2,000 of Cyclacel Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cyclacel Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cyclacel Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:UXI3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:UXI3 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cyclacel Pharmaceuticals has not reported any payouts.
  • Unable to verify if Cyclacel Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cyclacel Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cyclacel Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cyclacel Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cyclacel Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cyclacel Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cyclacel Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Spiro Rombotis
COMPENSATION $776,024
AGE 59
TENURE AS CEO 21.7 years
CEO Bio

Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Group Plc) since August 1997 and has been its Founding Chief Executive Officer since joining in August 1997. Mr. Rombotis also serves as Chief Executive of Cyclacel Limited. He has over 23 years of experience with pharmaceutical and biotechnology companies. He served as Chief Executive Officer and President of Xcyte Therapies Inc. Previously, he served as Vice President of International Operations and Business Development, Managing Director, Europe of Japanese joint venture, at The Liposome Company, Inc. He served as Vice President of Pharmaceuticals for Central and Eastern Europe and as Director of International Marketing of Bristol-Myers Squibb Company. He began his career in pharmaceuticals in Switzerland at the business development group of Ciba-Geigy AG, subsequently Novartis AG. He served as Head of European Marketing and Sales and Head of Corporate Development of Janssen Biotech, Inc. (formerly Centocor, Inc.) as well as working in Business Development of Novartis AG. He serves as a Director of BioNJ Inc. He has been Executive Director of Cyclacel Pharmaceuticals, Inc since March 2006. He serves on the Kellogg Biotech Advisory Board. He served as Director of Xcyte Therapies Inc. and Japanese joint venture, at Liposome Company, Inc. Mr. Rombotis holds a B.A. from Williams College, an M.B.A. and Master's degree in Hospital Management with honors, from the Kellogg Graduate School of Management.

CEO Compensation
  • Spiro's compensation has increased whilst company is loss making.
  • Spiro's remuneration is higher than average for companies of similar size in Germany.
Management Team

Spiro Rombotis

TITLE
President
COMPENSATION
$776K
AGE
59
TENURE
21.7 yrs

Paul McBarron

TITLE
Executive VP of Finance
COMPENSATION
$420K
AGE
57

Judy Chiao

TITLE
Vice President of Clinical Development & Regulatory Affairs
COMPENSATION
$538K
AGE
58
TENURE
13.9 yrs

Gill Christie

TITLE
Director of Human Resources
AGE
61

Robert Westwood

TITLE
Head of Preclinical Development and Vice President of Chemistry & Preclinical Development
AGE
74
Board of Directors Tenure

Average tenure and age of the Cyclacel Pharmaceuticals board of directors in years:

13.1
Average Tenure
69
Average Age
  • The average tenure for the Cyclacel Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

David U'Prichard

TITLE
Chairman
COMPENSATION
$92K
AGE
69

Spiro Rombotis

TITLE
President
COMPENSATION
$776K
AGE
59
TENURE
13.1 yrs

Chris Henney

TITLE
Vice Chairman
COMPENSATION
$80K
AGE
77

Paul McBarron

TITLE
Executive VP of Finance
COMPENSATION
$420K
AGE
57
TENURE
13.1 yrs

John Michael Banham

TITLE
Non-Executive Director
COMPENSATION
$64K
AGE
77
TENURE
13.1 yrs

Sam Barker

TITLE
Director
COMPENSATION
$62K
AGE
75
TENURE
4.6 yrs

Michel Marty

TITLE
Member of Scientific Advisory Board

Edward Sikora

TITLE
Member of Scientific Advisory Board
AGE
68

Kenneth Harrap

TITLE
Member of Scientific Advisory Board

Stanley Kaye

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Cyclacel Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cyclacel Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Details
Name: Cyclacel Pharmaceuticals, Inc.
UXI3
Exchange: DB
Founded: 1992
$10,818,386
17,199,974
Website: http://www.cyclacel.com
Address: Cyclacel Pharmaceuticals, Inc.
200 Connell Drive,
Suite 1500,
Berkeley Heights,
New Jersey, 07922,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CYCC Common Stock Nasdaq Capital Market US USD 28. Mar 2006
DB UXI3 Common Stock Deutsche Boerse AG DE EUR 28. Mar 2006
NasdaqCM CYCC.P PFD CONV EX 6% Nasdaq Capital Market US USD 29. Oct 2004
Number of employees
Current staff
Staff numbers
14
Cyclacel Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 20:57
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.